Abstract
BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P
| Original language | English |
|---|---|
| Pages (from-to) | 2001-2015 |
| Number of pages | 15 |
| Journal | New England Journal of Medicine |
| Volume | 357 |
| Issue number | 20 |
| DOIs | |
| Publication status | Published - Nov 15 2007 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Prasugrel versus clopidogrel in patients with acute coronary syndromes. / Wiviott, Stephen D.; Braunwald, Eugene; McCabe, Carolyn H.; Montalescot, Gilles; Ruzyllo, Witold; Gottlieb, Shmuel; Neumann, Franz Joseph; Ardissino, Diego; De Servi, Stefano; Murphy, Sabina A.; Riesmeyer, Jeffrey; Weerakkody, Govinda; Gibson, C. Michael; Antman, Elliott M.
In: New England Journal of Medicine, Vol. 357, No. 20, 15.11.2007, p. 2001-2015.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prasugrel versus clopidogrel in patients with acute coronary syndromes
AU - Wiviott, Stephen D.
AU - Braunwald, Eugene
AU - McCabe, Carolyn H.
AU - Montalescot, Gilles
AU - Ruzyllo, Witold
AU - Gottlieb, Shmuel
AU - Neumann, Franz Joseph
AU - Ardissino, Diego
AU - De Servi, Stefano
AU - Murphy, Sabina A.
AU - Riesmeyer, Jeffrey
AU - Weerakkody, Govinda
AU - Gibson, C. Michael
AU - Antman, Elliott M.
PY - 2007/11/15
Y1 - 2007/11/15
N2 - BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P
AB - BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P
UR - http://www.scopus.com/inward/record.url?scp=36148983750&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36148983750&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa0706482
DO - 10.1056/NEJMoa0706482
M3 - Article
C2 - 17982182
AN - SCOPUS:36148983750
VL - 357
SP - 2001
EP - 2015
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 20
ER -